MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Annals of Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,693 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,693 works in the cohort · of 4,299,418page 34 of 54

Labels cover 15 of 2,693 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,693 of 2,693 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
William Jacot, Hannah Savage, Susan Dent, Javier Cortés, Y-H Im, Véronique Dièras +8 more
2020· article· en· Annals of Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Nathalie Gaspar, Quentin Campbell‐Hewson, Stefan Bielack, Marty Campbell, Francisco Bautista, Cristina Meazza +12 more
2020· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
1223TiP A randomized phase III study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG-3098/ENGOT-EN24
B.M. Slomovitz, P. Follana, Melissa A. Geller, Elena Ioana Braicu, S. Ghamande, Ignacio A. Romero +12 more
2025· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
aboutno affunlabeled
Medical-aid-in-dying use in the US Pacific Northwest
Charles D. Blanke, Michael LeBlanc, Dawn L. Hershman, Frank L. Meyskens, Lloyd A. Taylor, Lee M. Ellis
2018· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
1
citations
← previousnext →

How this was built: Screen · Findings · About